New drug OVV-01 injected into tumors shows promise in early trial

NCT ID NCT07648472

Recruiting now Disease control Sponsor: Joint Biosciences Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while also looking for signs that the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OVV-01 (a drug injected into a vein or directly into a tumor)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 18 people, focused mainly on safety. It may not show clear benefit, and side effects are unknown. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.